A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)

Pharmacoepidemiological Study on the Use of Arcoxia® Under Actual Conditions of Use in France

This postmarketing study will examine the use of etoricoxib (Arcoxia®) in routine clinical practice in France as well as the use of celecoxib (Celebrex®).

Inclusion Criteria:

• Treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib
• Consent to take part in the study
• Included in his/her physician's client base for at least 1 year

Exclusion Criteria:

• Unable to receive follow-up over a year
• Included in an interventional trial